Immunotherapy in Breast Cancer: A Promising Avenue for Triple Negative Disease

Immunotherapy has been a relatively late addition to the treatment landscape for breast cancer, particularly when it comes to HER2-positive disease. Currently, there is no established role for immunotherapy in treating HER2-positive breast cancer.

Revolutionizing Treatment for Triple Negative Breast Cancer

However, immunotherapy has emerged as a powerful tool in managing triple negative breast cancer (TNBC). When combined with chemotherapy, it significantly elevates response rates, complete response rates, and crucially, the cure rate for these patients. This combination therapy is being utilized in various stages of the disease:

* **Neo-adjuvant Setting:** Before tumor removal
* **Adjuvant Setting:** After tumor removal
* **Metastatic Setting:** When cancer has spread

The decision to incorporate immunotherapy in metastatic TNBC often hinges on the PD-L1 expression level. If the CPS (Combined Positive Score) exceeds 10%, immunotherapy is typically added to chemotherapy.

Emerging Research and Future Directions

While immunotherapy’s primary application currently lies in TNBC, research continues to explore its potential in other breast cancer subtypes. Notably, a recent trial investigating ER-positive, HER2-negative breast cancer in a neo-adjuvant setting demonstrated promising improvements in response rates. However, this remains experimental and requires further validation.

In conclusion, immunotherapy has imporved the treatment landscape for TNBC, offering significant improvements in patient outcomes. While its role in other subtypes like HER2-positive remains under investigation, ongoing research holds promise for expanding immunotherapy’s application in breast cancer care.

This article has been reviewed and edited by Dr JP Minart